Brentuximab vedotin targets CD30, is internalized, and releases MMAE that binds the beta-tubulin (vinca) site to block microtubule polymerization, causing G2/M arrest and apoptosis. Killing is determined by CD30 targeting, not by beta-tubulin expression itself.